# Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial

> **NCT04820751** · PHASE3 · UNKNOWN · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 200 (estimated)

## Conditions studied

- Viral Pneumonia
- Serotonin Syndrome
- Platelet Dysfunction

## Interventions

- **DRUG:** Cyproheptadine Hydrochloride 4 MG

## Key facts

- **NCT ID:** NCT04820751
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-10
- **Primary completion:** 2021-11-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04820751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04820751, "Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04820751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*